Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7937781 | 1.00 | CYP4F2 (0.38) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL13264348 | 1.00 | CYP4F2 (0.38) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL2632363 | 0.98 | CYP4F2 (0.35) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL91152 | 0.95 | SMN1; SMN2 (0.35) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL19480944 | 0.91 | CYP4F2 (0.32) | CYP4F2CYP4A11TDP1 | |
| SCHEMBL15386615 | 0.81 | GGPS1 (0.40) | TSHR | |
| SCHEMBL11993646 | 0.81 | GGPS1 (0.40) | TSHR | |
| SCHEMBL14580411 | 0.81 | GGPS1 (0.40) | TSHR | |
| SCHEMBL17251187 | 0.79 | — | — | |
| SCHEMBL16124355 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | WANG SHU (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | LDLR, APOB, MSR1 | CYP4F2 2059/4885CYP4A11 1801/4885LMNA 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.